Alector, Inc. - Common Stock (ALEC)

Curious to know what's happening on the US markets one hour before the close of the markets on Friday? Join us as we explore the top gainers and losers in today's session.

Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Alector's AL002 misses primary endpoint in Alzheimer's trial. BofA downgrades stock, cuts price target, and highlights near-term challenges.

Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is cut by 17%.

ALEC stock results show that Alector beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.

We're starting Wednesday with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on this morning!